Brind.

The National Cancer Institute (NCI) estimates that KRAS mutations are present in approximately one-third of all cancers.

1 report, 1 independent Updated Aug 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Hoffmann-La Roche National Cancer Institute

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
National Cancer Institute
public hospital in Milan dedicated to cancer care
- PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Sun 13:48
- NI EH S, NCI, and NTP join a joint technical working group to strengthen scientific review through HHS/EPA partnership.Thu 18:58

Coverage

Newest first; wire copies grouped

Aug 14Clinical Trials ArenaElicio’s peptide cancer vaccine shows survival benefit in Phase I trial Elicio Therapeutics’ lead cancer vaccine asset, ELI-002, has been found to improve survival outcomes in patients with hard-to-t